Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives
Completed
- Conditions
- PainOpioid Induced Constipation
- Registration Number
- NCT01812733
- Lead Sponsor
- Mundipharma AB
- Brief Summary
The objective of the non-interventional study is to compare the quality of life, health care resource use and costs between the use of a combination of oxycodone and naloxone (Targiniq) versus oxycodone and laxatives for patients with severe pain, and to evaluate the cost-effectiveness of treatment with Targiniq.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 37
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quality of Life 8 Weeks Two visits performed over 8 weeks
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the mechanism of action of naloxone in Targiniq for opioid-induced constipation management?
How does Targiniq compare to standard oxycodone-laxative regimens in managing severe pain and constipation?
Are there specific biomarkers that predict patient response to Targiniq in chronic pain populations?
What adverse events are associated with Targiniq versus oxycodone with laxatives in pain management?
What are the cost-effectiveness outcomes of Targiniq in treating opioid-induced constipation compared to alternatives?
Trial Locations
- Locations (1)
Rehabiliteringsmedicinska kliniken
🇸🇪Örebro, Sweden
Rehabiliteringsmedicinska kliniken🇸🇪Örebro, Sweden